Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Creo Medical GroupCMEOF 29 3-1 Month Momentum % is N/A% as of Aug. 04, 2026. GuruFocus rates CMEOF with a GF Score™ of 29/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Creo Medical Group ranks better than 84.35% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Creo Medical Group's 3-1 Month Momentum % is N/A%.
The industry rank for Creo Medical Group's 3-1 Month Momentum % or its related term are showing as below:
CMEOF's 3-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -8.05 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Creo Medical Group (OTCPK:CMEOF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Creo Medical Group 3-1 Month Momentum % Related Terms
CMEOF vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Creo Medical Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's 3-1 Month Momentum % falls into.
Creo Medical Group (OTCPK:CMEOF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a 3-1 Month Momentum % of N/A% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #133 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 15.6%.
Is Creo Medical Group's 3-1 Month Momentum % too high?
Creo Medical Group's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Creo Medical Group ranks #133 out of 850 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Creo Medical Group has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #133 out of 850 companies for 3-1 Month Momentum %. This places Creo Medical Group in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Creo Medical Group (CMEOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.23 — trading 42.2% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. Creo Medical Group's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current 3-1 Month Momentum % is N/A% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.23 is trading 42.2% below its estimated GF Value™ of $0.39.
GuruFocus considers Creo Medical Group to be Possible Value Trap.
Key valuation signals for CMEOF:
3-1 Month Momentum %: N/A%
GF Value™: $0.39 vs. price of $0.23 (42.2% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
29GF Score
Get the complete analysis for CMEOF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
